RCT: Effects of intravenous Eptinezumab vs. placebo on headache pain and most bothersome symptom when initiated during a migraine attack.
18 Jun, 2021 | 08:16h | UTCEffects of Intraven.ous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Acute Treatment for Migraine: Contemporary Treatments and Future Directions (free for a limited period)
Commentary: Migraine Prevention Drug Eptinezumab Shows Efficacy in Treating Acute Attacks – Physician’s Weekly
Commentary on Twitter (thread – click for more)
Science marches breathlessly forward – or, at least tries to expand its indication.
Anti–calcitonin gene-related peptide antibody infusion, again, vs. placebo.
— Ryan Radecki, MD MS (@emlitofnote) June 17, 2021